Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3009798 | 1.00 | ALOX5 (0.50) | ALOX5ALDH1A1HDAC1PKMKMT2A | |
| SCHEMBL4944708 | 1.00 | ALOX5 (0.50) | ALOX5ALDH1A1HDAC1PKMKMT2A | |
| SCHEMBL348443 | 0.81 | ALOX5 (0.50) | ALOX5ALDH1A1PKMKMT2AMEN1 | |
| SCHEMBL348444 | 0.81 | ALOX5 (0.50) | ALOX5ALDH1A1PKMKMT2AMEN1 | |
| SCHEMBL453157 | 0.80 | ALOX5 (0.55) | ALOX5ALDH1A1PKMKMT2AMEN1 | |
| SCHEMBL453156 | 0.80 | ALOX5 (0.55) | ALOX5ALDH1A1PKMKMT2AMEN1 | |
| SCHEMBL453158 | 0.80 | ALOX5 (0.55) | ALOX5ALDH1A1PKMKMT2AMEN1 | |
| SCHEMBL1708187 | 0.78 | ALOX5 (0.58) | ALOX5ALDH1A1PKMKMT2AMEN1 | |
| SCHEMBL1285898 | 0.78 | ALOX5 (0.58) | ALOX5ALDH1A1PKMKMT2AMEN1 | |
| SCHEMBL3069141 | 0.78 | ALOX5 (0.58) | ALOX5ALDH1A1KMT2AMEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265106-B2 | Method for isolating (R)-tofisopam | VELA AQUISITION CORPORATION (US) | 2007-09-04 | — | — | US | claimed |
| US-20040254174-A1 | Method for isolating (R)-tofisopam | VELA PHARMACEUTICALS, INC. (US) | 2004-12-16 | — | — | US | claimed |
| EP-1968953-A2 | METHOD FOR ISOLATING (R)-TOFISOPAM | Vela Acquisition Corporation (US) | 2008-09-17 | — | — | EP | disclosed |
| US-7265106-B2 | Method for isolating (R)-tofisopam | VELA AQUISITION CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265106-B2 | Method for isolating (R)-tofisopam | VELA AQUISITION CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| WO-2007078808-A2 | METHOD FOR ISOLATING (R)-TOFISOPAM | VELA ACQUISITION CORPORATION (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20060128955-A1 | Method of isolating (R)-tofisopam | VELA PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | US | disclosed |
| US-20040254174-A1 | Method for isolating (R)-tofisopam | VELA PHARMACEUTICALS, INC. (US) | 2004-12-16 | — | — | US | disclosed |
| US-20040254174-A1 | Method for isolating (R)-tofisopam | VELA PHARMACEUTICALS, INC. (US) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254174-A1 | Method for isolating (R)-tofisopam | AMY1A, SI, IRS1 | ALOX5 3625/4885ALDH1A1 1809/4885HDAC1 2481/4885 |
| US-20060128955-A1 | Method of isolating (R)-tofisopam | NPEPPS, NPPA, THOP1 | ALOX5 3432/4885ALDH1A1 3345/4885HDAC1 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.